AISAP Cardio vs Us2.v2
AI Verdict
Choose AISAP Cardio if…
Choose AISAP Cardio if your primary need is rapid, comprehensive cardiac diagnostic assessment directly at the patient's bedside, particularly in point-of-care settings like emergency departments or critical care. This tool excels at providing immediate AI-powered interpretations and reports for early detection of structural heart disease and heart failure, facilitating quick clinical decisions where time is critical.
View AISAP Cardio →Choose Us2.v2 if…
Choose Us2.v2 if your goal is to achieve 100% AI automation for echocardiogram interpretation and reporting within a high-volume cardiology practice or imaging center. This solution is ideal for organizations seeking to drastically reduce manual reporting time, increase scan throughput, and ensure consistent, guideline-adherent reporting across a wide range of cardiac pathologies, with flexible deployment options.
View Us2.v2 →When considering AI-powered tools for cardiac assessment, physicians have strong options in AISAP Cardio and Us2.v2, each excelling in distinct areas. AISAP Cardio is designed for point-of-care ultrasound (POCUS), providing rapid, comprehensive cardiac diagnostic assessments and measurements directly at the bedside. Its strength lies in enabling early detection of structural heart disease and heart failure in acute settings, offering automated analyses, interpretations, and reports for various valvular pathologies and ventricular measurements. This tool is particularly suited for emergency medicine or critical care physicians who require immediate insights from POCUS exams.
In contrast, Us2.v2 focuses on automating the interpretation of full echocardiograms, delivering complete structured echo reports with measurements, disease detection, and clinical findings. Its key practical difference is 100% AI automation, which eliminates manual frame selection and annotation, significantly reducing reporting time and increasing daily scan throughput. Us2.v2 is compatible with any ultrasound manufacturer and offers both cloud and on-premise deployment, making it ideal for cardiology departments or practices seeking to streamline their echocardiography workflow and enhance the consistency and accuracy of their reporting. Physicians prioritizing efficiency and comprehensive, automated reporting for standard echocardiograms would likely find Us2.v2 to be the more fitting choice.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AISAP Cardio | Us2.v2 |
|---|---|---|
| Pricing | Not publicly available | Contact for pricing |
| Deployment | Cloud-based SaaS platform | Cloud, On-premise |
| FDA Status | 1 AI-estimated | 1 AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Us2.v2Us2.v2 explicitly highlights '100% AI automation, eliminating manual frame selection and annotation' and claims to 'reduce reporting time by up to 70%'. These features directly translate to a more streamlined and efficient user experience, significantly enhancing usability. While AISAP Cardio emphasizes 'rapid' assessments at the point of care, Us2.v2 provides more concrete metrics and features related to automation and time-saving for the interpretation process.
Clinical Value
Us2.v2Both tools are FDA-cleared and offer significant clinical value through automated cardiac assessments. However, Us2.v2 distinguishes itself by offering 'guideline-adherent and explainable AI with transparent visual overlays and editable outputs,' which enhances trust and clinical utility. Additionally, Us2.v2 specifically lists automated detection of cardiac amyloidosis and pulmonary hypertension, indicating a broader range of advanced diagnostic capabilities beyond what AISAP Cardio explicitly states.
Pricing & Value
TieNeither AISAP Cardio nor Us2.v2 provide publicly available pricing information, both requiring direct contact for a demo and quotation. Without specific pricing details or comparative case studies on return on investment, it is not possible to determine which tool offers better value. Therefore, they are tied in this dimension.
Enterprise Readiness
Us2.v2Us2.v2 demonstrates stronger enterprise readiness by explicitly stating HIPAA compliance and the availability of a Business Associate Agreement (BAA), which are crucial for healthcare organizations. Furthermore, Us2.v2 offers both cloud and on-premise deployment options, providing greater flexibility to integrate into diverse IT infrastructures compared to AISAP Cardio's stated cloud-based SaaS platform.
Innovation
Us2.v2While both tools leverage AI for cardiac ultrasound interpretation, Us2.v2 showcases slightly more advanced innovation with its '100% AI automation, eliminating manual frame selection and annotation' and 'guideline-adherent and explainable AI with transparent visual overlays'. These features suggest a deeper level of AI integration and transparency, pushing the boundaries of automated echocardiogram analysis.
Support & Docs
TieBased on the provided structured facts and web searches, there is no explicit information available for either AISAP Cardio or Us2.v2 regarding their specific support offerings or documentation libraries. Both companies provide general contact information, but a direct comparison of support quality or documentation comprehensiveness cannot be made.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AISAP Cardio | Us2.v2 |
|---|---|---|
| Name | AISAP Cardio | Us2.v2 |
| Company | Aisap | Eko.ai Pte. Ltd d/b/a Us2.ai |
| Primary Functionality | AI-powered point-of-care ultrasound (POCUS) software platform providing rapid, comprehensive cardiac diagnostic assessments and measurements. | AI-powered tool that automates echocardiogram interpretation, delivering a complete structured echo report with measurements, disease detection, and clinical findings. |
| Cardiac Conditions Detected/Measured | Assessment of valvular pathologies (mitral, tricuspid, aortic regurgitation, aortic stenosis), Measurement of Left Ventricle Ejection Fraction (LVEF), Measurement of right and left ventricular dimensions, atrial areas, ascending aorta diameter, and IVC diameter. | Automated detection of cardiac amyloidosis, aortic stenosis, heart failure, pulmonary hypertension, and valvular disease; delivers a complete structured echo report with measurements, disease detection, and clinical findings. |
| Vendor Compatibility | Vendor-agnostic and scalable solution | Compatible with any ultrasound manufacturer (e.g., GE, Philips, Siemens, handheld POCUS) |
| Integration | Integration with existing clinical workflows, EHR/EMR, and PACS | Integrates seamlessly with existing PACS, CVIS, or EMR systems (HL7 and DICOM SR supported) |
Videos
Demos, reviews, and walkthroughs featuring AISAP Cardio and Us2.v2.